Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals' stock has experienced significant movements. As of October 24, 2025, the share price was $29.97, a 106.40% increase over the past year. In early August 2025, Rigel reported strong second-quarter financial results, with total revenue of approximately $101.7 million, including net product sales of $58.9 million and contract revenues from collaborations of $42.7 million, leading to raised full-year sales guidance. The Q2 2025 results included $40.0 million in non-cash contract revenue from Eli Lilly and Company. As of October 27, 2025, the stock price was $29.58. Weiss Ratings reaffirmed a "Hold (C+)" rating, HC Wainwright & Co. reiterated a "buy" rating with a $57.00 target price, and Zacks Research cut Rigel Pharmaceuticals from a "strong-buy" to a "hold" rating.

There is no explicit indication of significant demand seasonality for Rigel Pharmaceuticals, Inc.'s products and services. Demand for its FDA-approved drugs is likely driven by ongoing medical need rather than seasonal patterns. Pharmaceutical product demand is typically more influenced by disease prevalence, treatment guidelines, market access, and competitive landscape than by seasonal variations.

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel small molecule drugs, primarily for hematologic disorders and cancer. Their commercialized products include Tavalisse for chronic immune thrombocytopenia, Rezlidhia for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation and Gavreto for metastatic RET fusion-positive non-small cell lung cancer and advanced thyroid cancers. The company also has pipeline candidates like R289 and collaborates with partners like Novo Nordisk, Blueprint Medicines Corporation, and Eli Lilly and Company.

Rigel Pharmaceuticals, Inc. is headquartered in South San Francisco, California, in the United States. The company's operational presence extends beyond the U.S. to include Europe, the UK, Canada, Israel, and Japan.

Rigel Pharmaceuticals' brand reputation is influenced by its financial performance and product advancements. Positive news sentiment is associated with strong Q2 2025 earnings and raised guidance, leading to a stock price increase. Continued growth in sales of FDA-approved drugs and progress in its pipeline contribute positively to its standing. Fluctuations in analyst ratings can influence investor perception. The overall media sentiment for Rigel Pharmaceuticals is tracked, indicating an ongoing assessment of public perception through news coverage.

Rigel Pharmaceuticals, Inc. has a significant institutional ownership presence, with 302 institutional owners and shareholders holding a total of 15,802,237 shares, representing 65% ownership. Major institutional owners include BlackRock, Inc., Armistice Capital, Llc, Morgan Stanley, Vanguard Group Inc, Soleus Capital Management, L.P., Acadian Asset Management Llc, State Street Corp, Capitolis Liquid Global Markets LLC and FMR LLC. Individual investors hold a 19% stake, while insiders own under 1% of the company.